Matinas BioPharma (NYSEAMERICAN:MTNB - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, Yahoo Finance reports.
Matinas BioPharma Price Performance
NYSEAMERICAN:MTNB traded down $0.02 during midday trading on Thursday, reaching $0.27. The stock had a trading volume of 1,209,751 shares, compared to its average volume of 1,246,901. Matinas BioPharma has a 12-month low of $0.11 and a 12-month high of $0.89. The firm has a market cap of $59.16 million, a price-to-earnings ratio of -2.48 and a beta of 1.52.
Institutional Investors Weigh In On Matinas BioPharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Atria Wealth Solutions Inc. acquired a new position in shares of Matinas BioPharma during the 1st quarter worth $32,000. HRT Financial LP increased its position in Matinas BioPharma by 320.5% during the 4th quarter. HRT Financial LP now owns 54,567 shares of the company's stock worth $27,000 after purchasing an additional 41,590 shares in the last quarter. Virtu Financial LLC purchased a new stake in Matinas BioPharma during the 2nd quarter worth about $73,000. Balyasny Asset Management LLC purchased a new stake in Matinas BioPharma during the 3rd quarter worth about $63,000. Finally, Renaissance Technologies LLC increased its position in Matinas BioPharma by 258.3% during the 4th quarter. Renaissance Technologies LLC now owns 121,096 shares of the company's stock worth $61,000 after purchasing an additional 87,296 shares in the last quarter. Institutional investors and hedge funds own 11.77% of the company's stock.
Matinas BioPharma Company Profile
(
Get Free Report)
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Recommended Stories
Before you consider Matinas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Matinas BioPharma wasn't on the list.
While Matinas BioPharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
